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Conventional drug development for treatment of cocaine addiction is greatly hindered by the extreme difficulty in designing a selective
cocaine antagonist. We employed anti-idiotypic (anti-Id) antibodies to generate cocaine antagonists. The purpose of this study was to
investigate the feasibility of this alternative approach. Herein, we describe the molecular cloning, bacterial expression, and functional
properties of an anti-Id monoclonal antibody (mAb), designated K2-3f, which possesses an internal image of cocaine within its variable
regions. The heavy and light chain variable domains of K2-3f were cloned by reverse transcription–polymerase chain reaction (RT-PCR)
and a single chain antibody variable fragment (scFv) was assembled for expression in Escherichia coli. The scFv bound to the human
dopamine transporter (hDAT) with moderate affinity (Ka = 5.3 106 M 1) and excellent mimicry of the cocaine molecule completely
inhibited cocaine binding at a molar concentration closely resembling in vivo conditions while allowing approximately 90% of equimolar
dopamine uptake. Our data suggest that the use of anti-Id antibody as a template for generation of a cocaine antagonist is a promising
approach well worth pursuing. If this strategy is successful, it could be applied to potential ligand–receptor interactions in the treatment of
other diseases.D 2003 Elsevier B.V. All rights reserved.Keywords: Anti-idiotypic antibody; Antigen mimicry; Cocaine; Cocaine analog; Dopamine transporter; Single chain antibody; scFv1. Introduction
Cocaine addiction remains a major threat to public health
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drug development is greatly hindered by the extreme diffi-
culty in designing a selective cocaine antagonist compound.
The addictive properties of cocaine are thought to result
from inhibition of dopamine re-uptake by the dopamine
transporter (DAT) in and around the synapses. By binding to
DAT, cocaine inhibits dopamine re-uptake and thus prolongs
signaling at key brain synapses. Despite intensive study, the
precise molecular mechanism of dopamine transport and of
its inhibition by cocaine remains unclear. Hydropathicity
analysis of DAT reveals a topology of 12 putative trans-
membrane domains with intracellularly oriented amino and
carboxyl termini [1,2]. Recent studies of DAT supporting
the existence of differential sites for dopamine translocation
and cocaine recognition [2–5] have given renewed incen-
tive to the search for cocaine antagonists. The ideal antag-
onist should bind DAT at the site of cocaine binding,
inhibiting cocaine binding, without interfering with dopa-
mine uptake, thus avoiding the physiological and behavioral
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structural classes of DAT ligands known was found to
fulfill this role. Rothman et al. [6] extended the search to
analog peptides by searching a random peptide library. Up
to now, the conventional search for the effective cocaine
antagonist that would spare dopamine transport has not been
successful.
An alternative approach for development of cocaine
antagonists is based on anti-idiotypic (anti-Id) antibodies
that possess an internal image of cocaine. We generated a
panel of such anti-Id monoclonal antibodies (mAbs) [7].
Several anti-Id mAbs bound to the human dopamine trans-
porter (hDAT) and inhibited dopamine uptake at levels
ranging from 40% to 90% of the inhibition given by cocaine
itself [8]. We surmised that the different levels of inhibition
produced by the various anti-Id mAbs may reflect the
different ways in which each antibody mimics the cocaine
molecule. It may also reflect the effect of steric hindrance: a
physical interference with dopamine uptake by the large
antibody molecule bound to the cocaine site.
The goal of this study was to investigate whether the
anti-Id antibodies could be used as a template for generating
cocaine antagonist peptides. To eliminate the possibility of
steric hindrance by a large molecule of antibody, we chose
to use the smallest fragments capable of retaining most
binding properties of the original antibody molecules, the
single chain antibody variable fragments (scFv). The anti-Id
mAb (K2-3f) shown to least interfere with dopamine uptake
was selected for producing scFv.2. Materials and methods
2.1. Cell lines
A neuroblastoma N1E-115 cell line stably expressing the
hDAT was generated and maintained in our laboratory as
described previously [8].
2.2. Establishment of mAbs
Ab1 and anti-Id Ab2 mAbs were produced as described
[7]. Ab2 ‘‘P1F5-1-A7’’ (K2-3f) hybridoma specific for
Ab1 (K2-3) was cloned twice by limiting dilution. mAb
isotypes were determined by enzyme-linked immunosor-
bent assay (ELISA) with reagents from an isotyping kit
(Southern Biotechnology Associates Inc., Birmingham,
AL). mAbs were purified following the published protocol
[7]. For in vitro binding assays, mAbs were dialyzed
overnight at 4 jC against PBS buffer.
2.3. Evaluation of cocaine from brain tissue by HPLC
The HPLC technique for extraction and evaluation of
cocaine from mouse brain tissue followed the protocol
described previously [7].2.4. Confocal immunofluorescence microscopy
N1E-115 cells grown to confluence on a six-well Costar
cell culture plate (Corning, NY) were rinsed with PBS and
fixed with 1% paraformaldehyde at room temperature for 30
min. After washing with PBS–Tween buffer, cells were
incubated in PBS–Tween 1% BSA buffer for 1 h. Cells
were then incubated with K2-3f (10 Ag/ml) and/or goat
polyclonal anti-hDAT IgG (sc-1433, Santa Cruz Biotech-
nology, Santa Cruz, CA) (20 Ag/ml) for 1 h, followed by
three washes (5 min each) with PBS–Tween buffer. The
anti-hDAT IgG recognizes an epitope mapping at the
carboxyl terminus (amino acid number: 601–620) of hDAT.
Cells were then incubated with FITC-conjugated anti-goat
IgG (KPL, MD) and PE-conjugated anti-mouse IgG (BD
PharMingen), both diluted 1:100, for 1 h and washed again.
All primary and secondary antibodies were diluted in PBS–
Tween 1% BSA buffer. The bottom of each well was cut and
mounted on a slide with cell side up. Confocal images were
generated on an Olympus FluoView 300 confocal laser
scanning system with an Olympus BX50 microscope at
the Center for Microscopy and Imaging at College of
Veterinary Medicine, University of Illinois.
2.5. Cloning of anti-Id mAb variable domains
Total mRNA was isolated from early passage K2-3f
hybridoma cells (1106) using the Quick Prep Micro
mRNA Purification Kit (Amersham Pharmacia Biotech).
Complementary DNA (cDNA) was produced from mRNA
using First-Strand cDNA Synthesis Kit (Amersham Pharma-
cia Biotech) and random hexanucleotide primers. Genes
coding for the variable domains were amplified from cDNA
by polymerase chain reaction (PCR). Briefly, the heavy chain
variable (VH) domain with its native signal sequence was
amplified using the degenerate primers MVH3 (5V-gggaatt-
cATGRAATGSASCTGGGTYWTYCTCTT-3V) and MVH4
(5V-cccaagcttCCAGGGRCCARKGGATARACIGRTGG-3V)
with initial 10 min denaturation at 94 jC followed by 30
cycles of 1 min denaturation at 94 jC, 1 min annealing at 45
jC, and 2 min extension at 72 jC. EcoRI and HindIII
restriction sites are underlined. Standard abbreviations have
been used for mixed sites: K, G, or T; M, A, or C; N, A, C, G,
or T; S, C, or G; R, A, or G; V, A, C, or G;W, A, or T; Y, C, or
T. The light (n) chain variable (VL) domain was amplified
under the same conditions using the primer pair MVL1 (5V-
gggaattcGAYATTGTGMTSACMCARWCTMCA-3V) and
MVL2 (5V-ggtaagcttGGATACAGTTGGTGCAGCATC-3V).
The VH or VL amplification product was digested with
EcoR1 and HindIII and ligated into the EcoR1–HindIII sites
of pETBlue-2 (Novagen) to yield plasmid pETBlue.K2-
3f.VH or pETBlue.K2-3f.VL. The VH and VL inserts were
sequenced using a 5V-primer (pETBlue2Up, 5V-GTCAC-
GACGTTGTAAAACGACGGCC-3V) by the W.M. Keck
Center for Comparative and Functional Genomics at the
University of Illinois.
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Sequence analyses were performed using the Biology
Workbench 3.2 utility (http://workbench.sdsc.edu/). The In-
ternational ImMunoGeneTics (IMGT) database (http://imgt.
cines.fr:8104/), and the Kabat database (http://immuno.
bme.nwu.edu/) were used to identify gene families and
groups of VH or VL. The complementarity-determining
regions (CDR) were assigned using the IMGT database.
The A/G-G-C/T-A/T and A-G-C/T sequences were identi-
fied as hot spots for somatic hypermutation and affinity
maturation.
2.7. Molecular modeling
The program WAM (http://antibody.bath.ac.uk/) [9] con-
taining a combined knowledge-based and energy-based
algorithm was used to generate the molecular model of
K2-3f. Briefly, three methods were used to perform the final
screen: the RMS deviation screen, the accessibility profile
screen, or energy only (backbone + side chains of the final
model). For side-chain modeling, two methods, the dead-
end elimination algorithm and the CONGEN iterative algo-
rithm, were used. CONGEN was used for the accessibility
profile screen and the VFF energy screen. Models made as
PDB files were visualized and analyzed using the VMD
(Visual Molecular Dynamics, Version 1.7) program (http://
www.ks.uiuc.edu/Research/vmd/) developed by the Theo-
retical Biophysics Group at the Beckman Institute of the
University of Illinois.
2.8. Assembly of scFv constructs
The scFv were constructed by a two-step overlap exten-
sion PCR (Fig. 3). Briefly, for the first step PCR, fragments
representing VH-Linker-VL N terminus were amplified by
PCR from K2-3f cDNA using primers MH105 (5V-
gcggccatggatCAAGTGAAGCTGGAGCAGTCTGGAGC-
T-3V) and MH106 (5V-TGGAGATTGTGTCATCACAAT-
ATCGGAACCACCACCACCGGAACCACCACCACCG-
GAACCACCACCACCATAGACAGATGGGGGTGT-
CGTTTT-3V) corresponding to the heavy chain framework
region (FR) 1 (MH105) and g1 constant region-linker-light
chain FR1 (MH106). Accordingly, fragments representing
VL-His6 were constructed by PCR amplification from K2-3f
cDNA using primers MH107 (5V-gcgGATATTGTGATGA-
CACAATCTCCA-3V) and MH104 (5V-gcgaagcttT-
CAGTGGTGGTGGTGGTGGTGGGATACAGTTGGTG-
CAGCATCAGC-3V) corresponding to the light chain FR1
(MH107) and n constant region-His6 (MH104). NcoI and
HindIII restriction sites are underlined. The cycling program
started with 94 jC for 10 min and continued with 30 cycles
of the following thermocycling conditions: 94 jC for 1 min,
68 jC for 1 min, and 72 jC for 2 min per cycle using Taq
DNA polymerase (Life Technologies). The amplified gene
fragments were purified (Qiagen) on 1% (w/v) agarose. Forthe second step overlap extension PCR, both 1st PCR
products, VH-Linker-VL N terminus and VL-His6, were
used as templates. Fragments representing the full-length
scFv were constructed by PCR amplification from the
mixture of the first PCR products using primers MH105
and MH104. The cycling program started with 94 jC for 10
min and continued with 30 cycles of the following thermo-
cycling conditions: 94 jC for 1 min, 68 jC for 1 min, and 72
jC for 2 min per cycle. After purification, PCR products of
scFv fragments were digested and inserted into the NcoI–
HindIII sites of pETBLue-2 (pETBlue.K2-3f.scFv) for se-
quence verification.
2.9. Bacterial expression and protein purification
The K2-3f scFv sequence was isolated from pET-
Blue.K2-3f.scFv as a NcoI–HindIII fragment and inserted
in frame to NcoI–HindIII site of bacterial expression vector
pET22b(+) (Novagen). The resulting pET22b.scFv.K2-3f
construct encodes a fusion protein consisting of the Escher-
ichia coli pelB signal peptide, the K2-3f scFv sequence, and
a hexahistidine tag. The scFv constructs were sequenced
and confirmed using a pair of 5V- and 3V-primers
(pET22bUp, 5V-TGCTGCTCCTCGCTGCCCAG-3V;
pET22bDown, 5V-GCCAACTCAGCTTCCTTTCG-3V).
Plasmid pET22b.scFv.K2-3f was transformed into the E.
coli strain BL21(DE3)pLysS. Bacterial clones were grown
in 1 l LB medium containing 100 Ag/ml ampicillin. When
induction was performed, bacterial cells transformed with
pET22b.scFv.K2-3f were first grown to an A600 of 0.7 at 37
jC, then 1 mM isopropyl h-D-thiogalactoside (IPTG) was
added. After 3 h of growth at 37 jC, cells were pelleted by
centrifugation and resuspended in 10 ml of BugBuster
buffer (Novagen) containing 10 Al Benzonase nuclease.
The cell suspension was incubated on a shaking platform
at a slow setting for 20 min at room temperature. Insoluble
cell debris were removed by centrifugation at 16,000 g
for 20 min at 4 jC. The soluble extract was applied to a
nickel-chelated agarose affinity column that had been
equilibrated with a nickel-binding buffer [20 mM Tris–
HCl (pH 7.9), 0.5 M NaCl, and 5 mM imidazole]. The
column was extensively washed with a wash buffer [20
mM Tris–HCl (pH 7.9), 0.5 M NaCl, and 60 mM
imidazole], the protein was eluted with elution buffer [20
mM Tris–HCl (pH 7.9), 0.5 M NaCl, 1 M imidazole] at a
flow rate of 0.5 ml/min, and 1-ml fractions were collected.
A sample (25 Al) was removed from each fraction and
analyzed by ELISA for the ability to bind Ab1 (K2-3).
Fractions containing binding activity were pooled, trans-
ferred to a dialysis cassette (molecular weight 10,000,
Pierce) and dialyzed against PBS buffer (pH 7.0) for 12
h at 4 jC. Protein concentration was determined using a
Bio-Rad protein assay kit with BSA as a standard. Purified
proteins were further analyzed by SDS–polyacrylamide
gel electrophoresis (SDS-PAGE), Western blot, and mass
spectrometry.
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Samples were electrophoresed through a 10% polyacryl-
amide gel under reducing conditions and electroblotted onto
a nitrocellulose transfer membrane (NitroPure, Osmonics,
Minnetonka, MN) with a Bio-Rad Mini Transblot apparatus
by standard techniques. After blocking the membrane with
5% non-fat dry milk in PBS containing 0.1% Tween 20,
protein was detected with horseradish peroxidase (HRP)-
labeled anti-His tag (specific for the His-His-His-His-His-
His at C terminus, Invitrogen) diluted 1:2500 followed by
ABTS substrate (KPL, MD). Blots were then washed three
times, and processed for chemiluminescence detection using
ECL reagent following the manufacturer’s (Amersham
Pharmacia Biotech) instructions. Photographic exposures
of 10 s to 2 min were made.
2.11. Mass spectrometry
Mass spectra were obtained on a Voyager mass spec-
trometer by using matrix-assisted laser desorption/ionization
(MALDI). Samples were dialyzed against 1 mM potassium
phosphate buffer, pH 8.0, and concentrated to 30 pmol/Al.
Analysis was performed by the Mass Spectrometry Labo-
ratory, School of Chemical Sciences, University of Illinois.
2.12. ELISA
Flat bottom microtiter plates (Immulon 2, Dynatech, VA)
were coated with 10 Ag/ml Ab1 K2-3 in carbonate buffer
(15 mM Na2CO3, 35 mM NaHCO3, 0.02% NaN3, pH 9.5)
and incubated overnight at 4 jC. Non-specific binding sites
were blocked by 1 h incubation at room temperature in
SuperBlock solution (Pierce, Rockford, IL). Fifty micro-
liters of the appropriate concentration scFv derived from the
anti-Id Ab2 mAb K2-3f were added to the wells and
incubated for 1 h at room temperature. The presence of
scFv binding to the Ab1 K2-3 was detected with an HRP-
labeled mAb to the His tag diluted 1:3000, followed by
ABTS substrate (KPL, MD). After 20 min, plates were read
at 410 nm with a Dynatech MR5000 ELISA reader (Dyna-
tech, Chantilly, VA). For the inhibition assay, soluble
cocaine or dopamine at the appropriate concentration was
added to Ab1 K2-3-coated wells and incubated for 1 h at
room temperature. The scFv was then added and incubated
for 1 h at room temperature. The assay was completed with
the detection system described above.
Binding of the scFv K2-3f on hDAT and competitive
inhibition assays with cocaine were performed essentially as
described above but on cell-coated plates instead of mAb-
coated plates. hDAT-transfected neuroblastoma cells (6C6)
grown at confluence in flasks were collected and seeded in
flat-bottom 96-well tissue culture plates. Forty-eight hours
later, the medium was discarded and the wells washed. The
cells were then fixed with 1% paraformaldehyde (100 Al/
well) for 30 min at room temperature.2.13. Determination of affinity constant (Ka)
The affinity constant of anti-Id mAb or scFv for the DAT
was determined by Scatchard plot [10] following the pro-
tocol described by Bator and Reading [11] using Fab or
scFv instead of the whole antibody molecule. Scatchard
plots were performed with Prism (Version 3.0.2, GraphPad
Software, San Diego, CA).
2.14. Dopamine uptake assays
Measurement of dopamine uptake was performed essen-
tially as previously described [8]. hDAT-transfected cells
were grown in 75-cm2 flasks for 3 days. After reaching
confluence, the cells were collected by trypsinization,
counted, distributed in 24-well plates (1105 per well)
and allowed to re-attach for 24 h. Following removal of
media from the wells, cells were washed at room tempera-
ture with 1 ml Krebs Phosphate (KP) buffer containing 5
mM Tris, 7.5 mM HEPES, 120 mM NaCl, 5.4 mM KCl, 1.2
mM CaCl2, 1.2 mM MgSO4, 1 mM ascorbic acid, 5 mM
glucose, at pH 7.1. Tritiated dopamine (ICN) in 0.5 ml of KP
buffer at a final concentration of 50 nM was added to wells,
and incubated for 5 min at 37 jC, after which, the assay
solution was promptly removed. The cells were washed
twice with 1 ml ice-cold KP buffer and dissolved in 0.4 ml
of 1% SDS. The entire liquid content of each well was
transferred to a scintillation vial with 5 ml Bio-SafeII
biodegradable cytoscint cocktail (RPI, Mt. Prospect, IL)
and assayed for radioactivity in a liquid scintillation counter
(Liquid Scintillation Analyzer, Packard Instruments, Down-
ers Grove, IL). For the inhibition assay, soluble cocaine,
anti-Id scFv K2-3f, or an irrelevant antibody Fab (anti-OVA)
at the appropriate concentration was added to cell-coated
wells and incubated for 10 min at room temperature. The
[3H]dopamine was then added and incubated for 5 min at 37
jC. The assay was completed as described above. Computer
analyses of dopamine uptake data and IC50 of competitors
were performed using Prism 3.0a program for Macintosh
(GraphPad Software).
2.15. Cocaine binding inhibition assays
Cells were grown and allowed to attach to 24-well
plates as described above. Following removal of media
from the wells, cells were washed at room temperature
with 1 ml KP buffer. Tritiated cocaine (provided by
NIDA, NIH through Research Triangle Institute) in 0.5
ml of KP buffer at a final concentration of 50 nM was
added to wells, and incubated for 5 min at 37 jC, after
which, the assay solution was promptly removed. Cells
were washed twice with 1 ml ice-cold KP buffer and
dissolved in 0.4 ml of 1% SDS. The entire liquid content
of each well was transferred to a scintillation vial and
assayed for radioactivity. For the inhibition assay, soluble
cocaine, anti-Id scFv, or an irrelevant Fab (anti-OVA) at
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incubated for 10 min at room temperature. The [3H] cocaine
was then added and incubated for 5 min at 37 jC. The assay
was completed as described above. Computer analyses of
cocaine binding data and IC50 of competitors were per-
formed using Prism 3.0a program for Macintosh (GraphPad
Software).3. Results
3.1. Production and characterization of anti-Id mAb K2-3f
The murine anti-Id mAb K2-3f (Ab2, hybridoma P1F5-
1-A7, IgGng1) was elicited by mAb K2-3 (Ab1, hybridoma
2B:B4) (Fig. 1A). Ab1 K2-3 was induced against the
cocaine hapten K2 coupled to keyhole limpet haemocyanin
(KLH) [7]. Conjugation to KLH occurred at position 1N of
the cocaine molecule; therefore, K2-KLH presented to the
immune system the methyl ester in the 2h-position and the
benzoyl in the 3h-position. It contains an intact tropane ring
(Fig. 1B).
The anti-Id nature of K2-3f was confirmed by both in
vitro and in vivo analyses: K2-3f bound to the K2-3 that
elicited it and its binding was inhibited by 1 mg/ml soluble
cocaine. When injected into Balb/c mice, K2-3f (Ab2)
induced high titers K2-3 (Ab1)-like Ab3 antibody specific
for cocaine. This response was sufficient to decrease (up to
60%) the amount of cocaine targeting the brains of immu-
nized mice after cocaine challenge compared to the amount
of cocaine reaching the brain of mice injected with an
irrelevant (anti-OVA) mAb.Fig. 1. (A) Schematic presentation of Ab1 mAb K2-3, anti-Id mAb (Ab2)
K2-3f, and scFv K2-3f generation. Hybridomas and scFv were produced as
described in the Materials and methods section. (B) Structures of cocaine
and the K2 hapten.3.2. Binding of K2-3f anti-Id mAb to hDAT: specificity and
affinity
To ascertain whether the K2-3f anti-Id mAb could
specifically bind to hDAT, an ELISA assay was performed
using a mouse neuroblastoma cell line (N1E-115) trans-
fected with the hDAT.
K2-3f showed the highest avidity to hDAT among a
panel of several Ab2 tested. The specificity and relative
avidity of K2-3f for hDAT can be surmised from the
inhibition patterns of its binding. Partial inhibition (20–
41%) was obtained with a high concentration of monomeric
cocaine (5 mg/ml); a more substantial level of inhibition
(60–66%) was obtained in the presence of a much lower
concentration of polymeric cocaine in the form of cocaine–
BSA conjugate (100 Ag/ml). Ten milligrams per milliliter of
BSA or a high concentration of dopamine (5 mg/ml) did not
produce any inhibition. These findings suggest that K2-3f
binds hDAT at the site of cocaine binding and that their
avidity for hDAT is stronger than that of soluble cocaine.
The K2-3f binding is also inhibited 87–93% by the K2-3
Ab1 mAb that elicited it, confirming that K2-3f binds hDAT
with its antigen combining sites. The binding affinity con-
stants of K2-3f (Ka = 2.7 107 M 1) for hDAT were deter-
mined by Scatchard plot analysis using Fab fragments.
The binding of K2-3f to hDAT was then confirmed by
confocal immunofluorescence microscopy. Fig. 2 distinctly
visualizes not only the binding, but also the position of
hDAT on the cell body. In Fig. 2B, the localization of the
K2-3f molecules incubated with the hDAT-transfected N1E-
115 neuronal cells is visualized by the addition of a PE-
conjugated anti-mouse IgG. In Fig. 2C, the same hDAT-
transfected N1E neuronal cells are stained with an anti-hDAT
polyclonal antibody and FITC-conjugated anti-goat IgG. In
Fig. 2F, double staining with the two systems unmistakably
confirms the co-localization of the hDAT and the K2-3f
molecules. Most fluorescence appears to be situated on the
cell membrane of the cell body, indicating that the hDAT
molecules, at high density, were mostly located on the cell
surface of N1E-115 cell bodies. Almost no fluorescence was
observed on the axon or dendrites.
3.3. Cloning and construction of K2-3f scFv
PCR products of the expected size (350–400 base pairs)
were obtained from amplification of K2-3f hybridoma
cDNA with VH (MVH3/4) and VL (MVL1/2) primers (see
Materials and methods). The nucleotide sequences have
been submitted to the GenBank with accession numbers
AF420003 (K2-3f VL), AF420004 (K2-3f VH). The VH
gene was cloned behind the pelB signal sequence, and the
VL gene was cloned in front of a sequence that encodes a 6-
histidine (His6) carboxyl-terminal tag (Fig. 3A). The His6
tag provides a convenient means of detecting K2-3f scFv
protein with the anti-His mAb. The scFv is flanked by 5V
NcoI and 3VHindIII sites to facilitate in-frame cloning of
Fig. 2. Confocal immunofluorescence microscopy demonstrating the binding of K2-3f to the mouse neuroblastoma N1E-115 cell line transfected with and
stably expressing hDAT. Cells were fixed with 1% paraformaldehyde (A) and incubated with: 10 Ag/ml K2-3f followed by PE-conjugated anti-mouse IgG (B),
20 Ag/ml of polyclonal goat anti-hDAT IgG followed by FITC-conjugated anti-goat IgG (C), both (F), and anti-OVA as a control (E). Untransfected N1E-115
cells as a background control were incubated with anti-hDAT antibody and then with FITC-conjugated anti-goat IgG antibody (D). Confocal images were
generated on an Olympus FluoView 300 confocal laser scanning system with an Olympus BX50 microscope. Bar, 50 mm.
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sequences of K2-3f scFv are shown in Fig. 3B.
3.4. Sequence analysis and molecular modeling
Sequence analysis using the IMGT database and the
Kabat database revealed that the amino acid sequences ofFig. 3. (A) Schematic presentation of the genetic construction of scFv K2-3f.
(B) Deduced amino acid sequence of the K2-3f scFv (GenBank accession
number AF479583). Arrow represents the cleavage site of signal peptide
pelB. Hot spots within CDR regions are indicated in italic type.the CDR1 and CDR2 of the K2-3f VH are very similar to
those of the IgHV1 germline gene (GenBank accession
number AAG39174); however, its CDR3 region (CDR-
H3) carries an insertion of two Arg, two Tyr, and two Phe
(Fig. 3B). It was reported that somatic insertions are usually
clustered at hot spots in the CDR regions [12,13] and the
inserted sequence is often a direct duplication of an adjacent
sequence (in most cases, only one or two amino acids). In
our case, a hot spot corresponding to amino acids Gly–Asn
was identified between two Tyr and two Phe which were
likely generated by somatic insertion during the affinity
maturation in vivo, clearly indicating the importance of
these inserted residues in antigen binding. The amino acid
sequence of the K2-3f VL, except for one amino acid in
FR1, is identical to that of the IgnV12 germline gene
(GenBank accession number AJ235956). The VH and VL
of K2-3f belong to the VH VII gene family (subgroup IIA)
and VL XVI (V), respectively. The primary sequence
analysis seems to indicate that the internal image of cocaine
is located within the CDR-H3 region of K2-3f. In future
work, focused on therapeutic applications, hot spots identi-
fied in the CDR regions, especially the one in CDR-H3,
may be a good candidate for in vitro affinity maturation of
K2-3f [14].
In addition to the primary sequence analysis, we gener-
ated the three-dimensional molecular model (Fig. 4) for K2-
3f VH and VL regions using the WAM program [9]. The
VFF energy screen was chosen for K2-3f. For side-chain
modeling, the CONGEN iterative algorithm was used. The
long CDR-H3 loop of K2-3f clearly has a major structural
implication for its combining site. Docking experiments
using the DockVision program, a combined Monte Carlo
and simulated annealing algorithm, revealed that K2-3f
Fig. 4. (A) Structural model of K2-3f V region. H1, 2, 3: heavy chain
CDR1, 2, 3; L1, 2, 3: light chain CDR 1, 2, 3. (B) Surface view of K2-3f V
region. Hot spot residues in the H3 region are Gly213 and Asn214.
Fig. 5. (A) SDS-PAGE analysis and Western blot of K2-3f scFv expressed
in E. coli. The purified scFv (lane 1) and molecular weight standards (lane
M, Bio-Rad) were electrophoresed under reducing conditions. In Western
blot, the protein was recognized by a peroxidase-labeled anti-His mAb (lane
2) as described in the Materials and methods section. (B) The precise
molecular mass was determined by MALDI mass spectrometry.
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at the tip of the CDR H3 loop interacting with the Ile207
and Tyr214 cleft of K2-3 (data not shown).
3.5. Expression and purification of K2-3f scFv
The pelB signal sequence was intended to facilitate
folding and purification by targeting the protein to the E.
coli periplasmic space. Prolonged (>3 h) IPTG induction
caused the release of scFv into the media. Media from
small-scale cultures were tested by ELISA on a K2-3 (Ab1)-
coated plate to establish that the presence of scFv could be
detected by the peroxidase-conjugated anti-His antibody. A
single positive clone (3F1) was selected for large-scale
fermentation and characterization.
K2-3f scFv was purified by nickel affinity chromatogra-
phy (Novagen) (see Materials and methods). One-milliliter
fractions were collected. A pool of fractions 1 and 2containing the highest concentration of elute was further
characterized by reduced SDS-PAGE gels and Western blot
analysis with the anti-His antibody (Fig. 5A). A major
overexpressed protein was present in the preparations. This
protein stained positive with the anti-His antibody by
Western blotting.
Mass spectrometry analysis indicated that the major
protein had a mass of 28,727.28 Da (Fig. 5B). The
molecular mass is consistent with the theoretical molecular
mass of the K2-3f scFv monomer (28.7 kDa) predicted by
the SAPS program (Biology WorkBench), assuming that
the pelB signal sequence at the N terminus has been
cleaved. The observed reactivity on a Western blot with
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terminus is intact. The estimated yield of nickel-purified
K2-3f scFv from a 1-l equivalent of fermentation is ap-
proximately 800 Ag.
3.6. Binding properties of K2-3f scFv
The binding of purified scFv K2-3f was tested by ELISA
on a K2-3 (Ab1)-coated plate and its binding affinity was
determined (Ka = 1.4 107 M 1). This suggests full trans-
lation of the N terminus of the native K2-3f’s antigen-
combining site. The scFv was recognized by anti-His
antibody, also suggesting full translation of the C terminus
of the recombinant protein. ScFv K2-3f (10 Ag/ml, 0.3 AM)
binding can be inhibited by cocaine (1 mg/ml, 3 mM) but
not by dopamine (1 mg/ml, 5 mM) (Fig. 6A). This clearly
indicates that the recombinant protein has retained the
internal image of cocaine, which characterizes the native
anti-Id mAb (K2-3f). We also found that both the unpurified
preparation of scFv (data not shown) and the purified scFv
bound specifically to the hDAT expressed on the surface of a
transfected neuroblastoma cell line in a manner similar to
the native K2-3f. Purified scFv K2-3f bound hDAT with a
binding affinity (Ka =f 5.3 106 M 1), approximately 5-Fig. 6. (A) Inhibition of scFv K2-3f binding to Ab1 mAb K2-3 by cocaine.
(B) Cocaine inhibition of scFv K2-3f binding to the hDAT expressed on the
surface of a transfected neuroblastoma N1E-115 cell line.fold lower than its native K2-3f Fab fragments. Neverthe-
less, the binding of K2-3f scFv to DAT (10 Ag/ml, 0.3 AM)
was inhibited by a high concentration of cocaine (3 mg/ml,
9 mM), suggesting that scFv bound DAT at the site of
cocaine binding and that its affinity for the DAT was
stronger than that of cocaine. Interestingly, we observed
that the binding of K2-3f could also be inhibited by a very
high concentration of dopamine (3 mg/ml, 15 mM) at some
degree (Fig. 6B). The unexpected dopamine inhibition was
likely caused by oxidation and precipitation of dopamine on
the N1E-115 cells during the prolonged incubation in
ELISA assays (Dr. Jianyong Li, personal communication).
In fact, we observed light or dark brown colors on neuro-
blastoma cells in the wells of dopamine at high concen-
trations. However, dopamine at a concentration lower than
0.5 mg/ml (2.5 mM) did not inhibit K2-3f binding to hDAT
(data not shown).
3.7. Inhibition of cocaine binding DAT by scFv K2-3f
To ascertain whether the K2-3f scFv could block cocaine
binding to DAT without interfering with dopamine uptake,
two assays, dopamine uptake and cocaine binding inhibi-
tion, were performed (see Materials and methods). Although
there is no widely accepted and validated assay for detecting
a cocaine antagonist, several strategies have been used to
obtain ‘‘uptake-to-binding ratios’’. One major strategy to
determine such ratio is to compare the IC50 value of a test
agent for inhibition of [3H]dopamine uptake and its IC50
value for inhibition of the binding of a transporter ligand
such as cocaine or a cocaine analog. The goal of such a
comparison is to identify a selective agent which has a high
‘‘uptake-to-binding’’ ratio. In our system, we observed that
K2-3f IC50 for [
3H]dopamine uptake was 550F 102 and
7.0F 1.4 nM for [3H]cocaine binding while cocaine IC50
for [3H]dopamine uptake was 32F 1.6 and 85F 14 nM for
[3H]cocaine binding. Therefore, the ‘‘uptake-to-binding ra-
tio’’ of K2-3f was approximately 80. It is noteworthy that in
the present study, following an approach originally proposed
by Rothman et al. [15], we conducted the dopamine uptake
and cocaine binding assays under identical conditions. We
found that our cocaine IC50 values for uptake and binding
were lower than those (95 nM for uptake and 104 nM for
binding) obtained in a similar system but under different
conditions [16]. Nevertheless, such IC50-based ratios must
be evaluated with caution because experimental conditions
used in these assays are often not close to in vivo situation.
Therefore, a better approach must be to conduct the assays
in a condition similar to in vivo setting [15]. Previous
studies using cocaine or cocaine analog compounds have
indicated the concentration and occupancy of the dopamine
transporter in humans: 13–47 nM [17] or 60 nM [18]. To
resemble as much as possible in vivo conditions, we chose
to use 50 nM for both dopamine uptake and cocaine binding
assays. As shown in Fig. 7A, 50 nM K2-3f scFv completely
inhibited 50 nM cocaine binding to DAT while allowing
Fig. 7. (A) Inhibition of cocaine (50 nM) binding to DAT by 50 nM K2-3f
scFv. A hundred percent inhibition was defined with 100 AM unlabeled
cocaine (147–487 cpm). The hundred percent cocaine binding was defined
with KP buffer only (1203–1921 cpm). (B) Effects of 50 nM K2-3f scFv or
cocaine on 50 nM dopamine uptake. Zero percent dopamine uptake was
defined with 100 AM unlabeled cocaine (881–1640 cpm). The hundred
percent dopamine uptake was defined with KP buffer only (6111–10314
cpm). (C) Effect of 50 nM K2-3f scFv on 50 nM dopamine uptake in the
presence of 100 AM cocaine. Error bars represent the standard deviation of
three determinations. Within each experiment, comparison of raw data of
the scFv K2-3f group to its control (A, C: anti-OVA mAb Fab; B: cocaine)
gave P values of *P< 0.005, **P< 0.001 (Student’s t-test, SigmaPlot,
Version 8.0).
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In contrast, 50 nM cocaine allowed only about 30% equi-
molar dopamine uptake. More interestingly, while 100 AM
cocaine alone completely inhibited 50 nM dopamine uptake,
the presence of 50 nM K2-3f scFv significantly neutralizedthe effect of cocaine by allowing about 60% dopamine
uptake (Fig. 7C).4. Discussion
We report here the production and characterization of an
anti-Id scFv (K2-3f). The K2-3f scFv mimics the configu-
ration of the cocaine molecule and binds hDAT at the site of
cocaine binding with higher affinity than cocaine. More
importantly, the scFv, at a low molar concentration similar
to in vivo conditions, by binding hDAT completely inhibits
cocaine binding while allowing equimolar dopamine uptake.
This makes it a possible novel cocaine antagonist.
The idiotypic network theory implies that the ‘‘internal
image’’ of anti-Id antibodies can mimic ‘‘any’’ antigen in
the ‘‘outside world’’ [19,20]. During the past two decades,
numerous anti-Id antibodies mimicking protein antigens
have been obtained (reviewed in Ref. [21]). In contrast,
only a few anti-Id antibodies with the internal images of
non-protein organic compounds have been reported [22–
25]. In the present study, we confirm that the scFv engi-
neered from anti-Id mAb K2-3f mimics the configuration of
cocaine (339.8 Da), maintains the characteristics of the
native anti-Id mAb, and binds to DAT, the major target of
cocaine in the brain. Obviously amino acid sequence ho-
mology between such a small non-protein antigen and an
antibody’s internal image cannot be expected. Mimicry must
therefore be based on conformation or electrochemical
effects rather than sequence homology [26]. The finding
that a polypeptide can mimic cocaine may possibly suggest
that cocaine may act as a peptidomimetic compound that
interferes with the function of an unknown endogenous
polypeptide in the brain.
Sequence analysis and structural modeling indicated that
CDR3 of K2-3f (ARRRTYYGNFFD), especially Tyr211–
Tyr212, might be the critical component of the internal
image of cocaine. Further studies using appropriate peptides
[27] derived from this putative internal image of cocaine
will be needed to confirm this prediction.
Initially, two anti-Id mAbs (K1-4c and K2-3f ) chosen for
construction of the scFv molecules, because of their low
interference with dopamine uptake [8], were successfully
constructed and expressed in the same bacterial system.
However, scFv K1-4c, while still weakly bound to the Ab1
mAb (K1-4) used to generate it, lost most of the binding
affinity shown by its native mAb for hDAT (data not
shown). These results may indicate that not all scFv con-
structs keep the internal images of their native anti-Id mAbs
faithfully. The non-linear complexity of the internal image
structure may be critical for the success of this approach.
The use of the K2-3f scFv as a therapeutic cocaine
inhibitor may be a debatable issue. However, cutting-edge
research suggests that the delivery of scFv to the brain
through the blood-brain barrier (BBB) may be a realistic
goal. Although peptides with the appropriate physicochem-
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antibodies (150 kDa) or their F(abV)2 (100 kDa) or Fab (50
kDa) fragments cannot be delivered without modification.
Current research efforts in the field of drug delivery to the
brain have developed some strategies to facilitate the
passage of peptides such as Fab fragments through the
BBB. Among them, cationization, which increases a pep-
tide’s positive electrical charge, facilitates peptide binding to
the negative charges on the surface of the endothelial cells
and has been widely described as a promising technique
[29]. It is also possible that in the clinical situation, the
passage of anti-Id scFv through the BBB will not present
any problem, since cocaine abuse and the consequent
opening of the BBB have been implicated in the observed
increase in neuroinvasion of the HIV-1 virus and monocyte
migration in the brain of chronic cocaine users [30].
On the other hand, the use of anti-Id antibody as a
template for generation of effective cocaine analogs is a
promising approach well worth pursuing. If this strategy is
successful, it could be applied to potential ligand–receptor
interactions in the treatment of other drug addictions (e.g.,
nicotine, heroin) and diseases. In fact, the use of internal
image for drug design has been largely overlooked. This
study addresses the intriguing possibility of using the
internal images of our anti-Id antibody molecules for the
design of cocaine antagonists.
We also think that the internal image of cocaine may
serve as a novel and unique molecular probe toward the
elucidation of the interaction of cocaine with hDAT. Func-
tional properties of K2-3f presented in this report suggest
the existence of a distinct cocaine binding site (possibly not
involved in dopamine uptake) recognized by this anti-Id
mAb. Binding domain mapping of K2-3f on hDAT is
currently in progress in our laboratory. Since the precise
binding site of cocaine on DAT has not yet been determined,
mapping the binding site of K2-3f on hDAT would possibly
greatly enhance our understanding of the complicated inter-
action of cocaine with the transporter.Acknowledgements
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